The global age-related macular degeneration (AMD) market was valued at $9.4 billion in 2022 and is projected to reach $15.4 billion by 2032, growing at a CAGR of 5% from 2023 to 2032. Age-related macular degeneration (AMD) is a common eye condition that affects millions of people across the globe, particularly those aged 50 and above. It is a progressive disease that affects the macula, which is the central part of the retina responsible for sharp, central vision. The two main types of age-related macular degeneration (AMD) are dry and wet age-related macular degeneration (AMD). Dry age-related macular degeneration (AMD), the most common type of age-related macular degeneration (AMD), occurs when the light-sensitive cells in the macula break down and die over time, causing a gradual loss of central vision. Wet age-related macular degeneration (AMD), a less common but more severe form of age-related macular degeneration (AMD), occurs when abnormal blood vessels grow beneath the retina and leak fluid, blood, and protein, causing scarring and damage to the macula.
The key factors that drive the growth of age-related macular degeneration (AMD) market are Increase in the geriatric population, surge in demand for effective treatment options, and technological advancement. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over. By 2050, the world population of people aged 60 years and older is projected to be 2.1 billion. The number of people aged 80 years or older is expected to reach 426 million by 2050. In addition, rise in the demand for age related macular degeneration drugs for the treatment dry age-related macular degeneration (AMD) across the world further boost the growth of the market.
However, high cost associated with age related macular degeneration drugs is projected to impede the market growth in upcoming years. On the contrary, Increase in R&D activities in age-related macular degeneration (AMD) treatment, and latest product approvals are expected to provide lucrative opportunities for the growth of the market in the near future.
The age-related macular degeneration (AMD) market is segmented into drug type, disease type, distribution channels and region. On the basis of drug type, the market is categorized into aflibercept, ranibizumab and others. On the basis of disease type, the market is bifurcated into dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). On the basis of distribution channels, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major key players that operate in the global age-related macular degeneration (AMD) market are Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Bausch Health Companies Inc, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals and Ionis Pharmaceuticals, Inc.
The key factors that drive the growth of age-related macular degeneration (AMD) market are Increase in the geriatric population, surge in demand for effective treatment options, and technological advancement. For instance, according to the 2022 factsheet of World Health Organization, by 2030, 1 in 6 people in the world is projected to be aged 60 years or over. By 2050, the world population of people aged 60 years and older is projected to be 2.1 billion. The number of people aged 80 years or older is expected to reach 426 million by 2050. In addition, rise in the demand for age related macular degeneration drugs for the treatment dry age-related macular degeneration (AMD) across the world further boost the growth of the market.
However, high cost associated with age related macular degeneration drugs is projected to impede the market growth in upcoming years. On the contrary, Increase in R&D activities in age-related macular degeneration (AMD) treatment, and latest product approvals are expected to provide lucrative opportunities for the growth of the market in the near future.
The age-related macular degeneration (AMD) market is segmented into drug type, disease type, distribution channels and region. On the basis of drug type, the market is categorized into aflibercept, ranibizumab and others. On the basis of disease type, the market is bifurcated into dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). On the basis of distribution channels, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major key players that operate in the global age-related macular degeneration (AMD) market are Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Bausch Health Companies Inc, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals and Ionis Pharmaceuticals, Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the age related macular degeneration (amd) market analysis from 2022 to 2032 to identify the prevailing age related macular degeneration (amd) market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the age related macular degeneration (amd) market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global age related macular degeneration (amd) market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
- Aflibercept
- Ranibizumab
- Others
By Disease Type
- Wet Age Related Macular Degeneration (AMD)
- Dry Age Related Macular Degeneration (AMD)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- F. Hoffmann-La Roche Ltd.
- Coherus Biosciences Inc
- Biogen
- Regeneron Pharmaceuticals Inc.
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Bayer AG
- Bausch Health Companies Inc.
- Apellis Pharmaceuticals Inc.
- Sanofi S.A.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE
CHAPTER 5: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE
CHAPTER 6: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Age Related Macular Degeneration (AMD) Market,' The age related macular degeneration (amd) market was valued at $9.4 billion in 2022, and is estimated to reach $15.4 billion by 2032, growing at a CAGR of 5% from 2023 to 2032.Age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, the central part of the retina responsible for sharp central vision. While the exact cause of AMD is not fully understood, there are several factors that contribute to its development. The primary risk factor for AMD is advancing age. As individuals get older, the risk of developing AMD increases. Genetics also play a role, as certain gene variations have been associated with an increased susceptibility to AMD. Other risk factors include smoking, high blood pressure, obesity, and a diet low in antioxidants and omega-3 fatty acids. AMD is characterized by the accumulation of waste materials, such as drusen, in the macula. These deposits can lead to damage and deterioration of the macular cells, resulting in vision loss. The underlying mechanisms behind the formation of drusen and the subsequent cellular damage are still being studied. There are two main types of AMD dry AMD and wet AMD.
The key factors that drive the growth of age-related macular degeneration (AMD) market are increase in the geriatric population, rise in incidence AMD of and surge in demand for effective treatment options. The aging population is a significant driver of AMD market growth. As individuals grow older, the risk of developing AMD increases. The global population is experiencing a demographic shift, with a larger proportion of people reaching the age group susceptible to AMD. This increase in the elderly population directly translates to a higher prevalence of AMD cases. For instance, according to an article by World Health Organization (WHO) published in October 2022, it was estimated that 1 in 6 people in the world to be aged 60 years or over by 2040. In addition, the prevalence and incidence of AMD have been steadily rising in recent years, primarily due to various factors. One contributing factor is the prolonged life expectancy observed worldwide. As people live longer, the cumulative exposure to risk factors for AMD, such as oxidative stress, inflammation, and genetic predisposition, increases. Additionally, changing lifestyles, including unhealthy diets, sedentary behavior, and smoking, contribute to the rising incidence of AMD. Furthermore, the increasing prevalence of chronic diseases like diabetes, hypertension, and cardiovascular disease, which are risk factors for AMD, also adds to the burden of AMD cases. The combination of these factors leads to a larger population affected by AMD, driving the growth of the AMD market.
The market also offers growth opportunities to the key players in the market. The increase in the number of pipeline drugs targeting age-related macular degeneration (AMD) is indeed a major growth opportunity in AMD market. The development of new pipeline drugs offers expanded treatment options for AMD patients. Currently, the primary treatment for neovascular or 'wet' AMD involves anti-vascular endothelial growth factor (anti-VEGF) injections. However, not all patients respond optimally to these treatments, and some may experience a decline in effectiveness over time. The introduction of new drugs in the pipeline provides alternative mechanisms of action, such as targeting different angiogenic factors or inflammation pathways, which can potentially improve treatment outcomes and patient response rates. The availability of a wider range of treatment options enhances the overall management of AMD and contributes to market growth.
Moreover, several drug manufacturers are looking for novel treatments since age-related macular degeneration (AMD) becomes increasingly prevalent. More than 10 age-related macular degeneration (AMD) medications are in the pipeline at various stages of development, and multiple corporations are currently working on treatments for AMD. ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, and more potential medications are in phases III and II.
Furthermore, significant advancements in diagnostic techniques, imaging technologies, and treatment modalities have greatly influenced the growth of the AMD market. Early detection and accurate monitoring of AMD are crucial for effective management and preservation of vision. Advanced imaging tools, such as optical coherence tomography (OCT), allow for high-resolution visualization of the retina, enabling ophthalmologists to detect and monitor early signs of AMD, such as drusen and retinal thinning. OCT has revolutionized the diagnosis and management of AMD, facilitating timely intervention and improving patient outcomes.
The age-related macular degeneration (AMD) market is segmented into drug type, disease type, distribution channels and region. On the basis of drug type, the market is categorized into aflibercept, ranibizumab and others. On the basis of disease type, the market is bifurcated into dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). On the basis of distribution channels, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
The key players profiled in the study include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Bausch Health Companies Inc, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals and Ionis Pharmaceuticals, Inc.
Key Market Insights
- On the basis of product type, the aflibercept segment was the highest contributor to the market in 2022.
- On the basis of disease type, the wet age-related macular degeneration segment dominated the market in terms of revenue in 2022. However, the dry Age-Related Macular Degeneration (AMD) segment is anticipated to grow at the highest CAGR during the forecast period.
- On the basis of distribution channel, the retail pharmacy segment was highest contributor to the market in 2022.
- On the basis of region, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Coherus Biosciences Inc
- Biogen
- Regeneron Pharmaceuticals Inc.
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Bayer AG
- Bausch Health Companies Inc.
- Apellis Pharmaceuticals Inc.
- Sanofi S.A.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 251 |
| Published | May 2023 |
| Forecast Period | 2022 - 2032 |
| Estimated Market Value ( USD | $ 9.4 billion |
| Forecasted Market Value ( USD | $ 15.4 billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
